As of 2025-05-15, the Intrinsic Value of Palla Pharma Ltd (PAL.AX) is (104.72) AUD. This PAL.AX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.30 AUD, the upside of Palla Pharma Ltd is -35,599.10%.
The range of the Intrinsic Value is (920.52) - (56.15) AUD
Based on its market price of 0.30 AUD and our intrinsic valuation, Palla Pharma Ltd (PAL.AX) is overvalued by 35,599.10%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (920.52) - (56.15) | (104.72) | -35599.1% |
| DCF (Growth 10y) | (381.35) - (6,677.37) | (734.95) | -249234.0% |
| DCF (EBITDA 5y) | (28.60) - (33.44) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (210.97) - (270.25) | (1,234.50) | -123450.0% |
| Fair Value | -1.82 - -1.82 | -1.82 | -716.03% |
| P/E | (7.38) - (6.69) | (7.05) | -2490.2% |
| EV/EBITDA | (1.61) - (1.77) | (1.68) | -668.3% |
| EPV | (0.48) - (0.64) | (0.56) | -289.1% |
| DDM - Stable | (4.43) - (28.87) | (16.65) | -5743.2% |
| DDM - Multi | (23.58) - (121.88) | (39.78) | -13584.9% |
| Market Cap (mil) | 47.76 |
| Beta | 1.18 |
| Outstanding shares (mil) | 161.91 |
| Enterprise Value (mil) | 62.42 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.35% |
| Cost of Debt | 4.31% |
| WACC | 6.14% |